LIVIVO - Search results -

Search results

Result 1 - 10 of total 14

Search options

Article ; Online: Neurokinin-1 receptor: a new promising target in the treatment of cancer.

Muñoz, Miguel / Coveñas, Rafael

Discovery medicine

2010 Volume 10, Issue 53, Page(s) 305–313

Abstract: ... antitumoral agent; 4) the NK-1 receptor could be a new promising target in the treatment of cancer; 5) NK-1 receptor ... antagonists could improve cancer treatment--the development of antagonist molecules of the NK-1 receptor ... NK-1) receptor, SP regulates biological functions related to cancer: tumor cell proliferation ...

Abstract	Substance P (SP) has a widespread distribution in the whole body. After binding to the neurokinin-1 (NK-1) receptor, SP regulates biological functions related to cancer: tumor cell proliferation (favoring tumor growth), angiogenesis, and migration of the tumor cells for invasion and metastasis. SP also exerts an antiapoptotic effect. The peptide is secreted from primary tumors and from peripheral nerves, and reaches the whole body through the blood stream. NK-1 receptors are overexpressed in tumors (cancer cells express more NK-1 receptors than normal cells). By contrast, after binding to NK-1 receptors, the NK-1 receptor antagonists specifically inhibit tumor cell proliferation (tumor cells die by apoptosis), angiogenesis and the migration of the tumor cells. Thus, 1) the SP/NK-1 receptor system plays an important role in the development of cancer, angiogenesis, and metastasis; 2) a common mechanism for cancer cell proliferation mediated by the SP/NK-1 receptor system occurs; 3) NK-1 receptor antagonists act as a broad-spectrum antitumoral agent; 4) the NK-1 receptor could be a new promising target in the treatment of cancer; 5) NK-1 receptor antagonists could improve cancer treatment--the development of antagonist molecules of the NK-1 receptor represents an important opportunity for exploiting these molecules as novel therapeutic agents.
MeSH term(s)	Animals ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Humans ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; Neoplasms/blood supply ; Neoplasms/drug therapy ; Neoplasms/pathology ; Neurokinin-1 Receptor Antagonists ; Receptors, Neurokinin-1/genetics ; Receptors, Neurokinin-1/metabolism ; Receptors, Neurokinin-1/physiology ; Substance P/genetics ; Substance P/metabolism ; Substance P/physiology
Chemical Substances	Antineoplastic Agents ; Neurokinin-1 Receptor Antagonists ; Receptors, Neurokinin-1 ; Substance P (33507-63-0)
Language	English
Publishing date	2010-10
Publishing country	United States
Document type	Evaluation Studies ; Journal Article ; Research Support, Non-U.S. Gov't ; Review
ISSN	1944-7930
ISSN (online)	1944-7930
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.

Isorna, Inmaculada / González-Moles, Miguel Ángel / Muñoz, Miguel / Esteban, Francisco

Journal of clinical medicine

2023 Volume 12, Issue 19

Abstract: ... of TC, targeting this receptor represents a promising therapeutic approach for TC. Therefore, NK-1R ... established that the neurokinin-1 receptor (NK-1R) is overexpressed in cancer cells and that NK-1R is ... antagonists, such as the drug aprepitant, may represent novel drugs for TC treatment. ...

Abstract	In recent years, numerous approaches have been developed to comprehend the molecular alterations underlying thyroid cancer (TC) oncogenesis and explore novel therapeutic strategies for TC. It is now well established that the neurokinin-1 receptor (NK-1R) is overexpressed in cancer cells and that NK-1R is essential for the viability of cancer cells. The binding of substance P (SP) to NK-1R in neoplastic cells plays a pivotal role in cancer progression by promoting neoplastic cell growth, protecting tumor cells from apoptosis, triggering invasion and metastasis through the enhanced migration of cancer cells, and stimulating endothelial cell proliferation for tumor angiogenesis. Remarkably, all types of human TC (papillary, follicular, medullary, anaplastic), as well as metastatic lesions, exhibit the overexpression of SP and NK-1R compared to the normal thyroid gland. TC cells synthesize and release SP, which exerts its multiple functions through autocrine, paracrine, intracrine, and neuroendocrine processes, including the regulation of tumor burden. Consequently, the secretion of SP from TC results in increased SP levels in plasma, which are significantly higher in TC patients compared to controls. Additionally, NK-1R antagonists have demonstrated a dose-dependent antitumor action. They impair cancer cell proliferation on one side and induce apoptosis of tumor cells on the other side. Furthermore, it has been demonstrated that NK-1R antagonists inhibit neoplastic cell migration, thereby impairing both invasiveness and metastatic abilities, as well as angiogenesis. Given the consistent overexpression of NK-1R in all types of TC, targeting this receptor represents a promising therapeutic approach for TC. Therefore, NK-1R antagonists, such as the drug aprepitant, may represent novel drugs for TC treatment.
Language	English
Publishing date	2023-10-09
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm12196409
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Substance P and Neurokinin-1 Receptor System in Thyroid Cancer

Inmaculada Isorna / Miguel Ángel González-Moles / Miguel Muñoz / Francisco Esteban

Journal of Clinical Medicine, Vol 12, Iss 6409, p

Potential Targets for New Molecular Therapies

2023 Volume 6409

Abstract	In recent years, numerous approaches have been developed to comprehend the molecular alterations underlying thyroid cancer (TC) oncogenesis and explore novel therapeutic strategies for TC. It is now well established that the neurokinin-1 receptor (NK-1R) is overexpressed in cancer cells and that NK-1R is essential for the viability of cancer cells. The binding of substance P (SP) to NK-1R in neoplastic cells plays a pivotal role in cancer progression by promoting neoplastic cell growth, protecting tumor cells from apoptosis, triggering invasion and metastasis through the enhanced migration of cancer cells, and stimulating endothelial cell proliferation for tumor angiogenesis. Remarkably, all types of human TC (papillary, follicular, medullary, anaplastic), as well as metastatic lesions, exhibit the overexpression of SP and NK-1R compared to the normal thyroid gland. TC cells synthesize and release SP, which exerts its multiple functions through autocrine, paracrine, intracrine, and neuroendocrine processes, including the regulation of tumor burden. Consequently, the secretion of SP from TC results in increased SP levels in plasma, which are significantly higher in TC patients compared to controls. Additionally, NK-1R antagonists have demonstrated a dose-dependent antitumor action. They impair cancer cell proliferation on one side and induce apoptosis of tumor cells on the other side. Furthermore, it has been demonstrated that NK-1R antagonists inhibit neoplastic cell migration, thereby impairing both invasiveness and metastatic abilities, as well as angiogenesis. Given the consistent overexpression of NK-1R in all types of TC, targeting this receptor represents a promising therapeutic approach for TC. Therefore, NK-1R antagonists, such as the drug aprepitant, may represent novel drugs for TC treatment.
Keywords	neurokin-1 receptor ; substance P ; tachykinin ; thyroid gland ; thyroid cancer ; Medicine ; R
Subject code	610
Language	English
Publishing date	2023-10-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?

Robinson, Prema / Coveñas, Rafael / Muñoz, Miguel

Current medicinal chemistry

2022 Volume 30, Issue 16, Page(s) 1798–1812

Abstract: ... a potential target for the treatment of cancer. Aprepitant combined with major chemotherapeutic drugs has ... of chemotherapy. The substance P (SP)/neurokinin-1 receptor (NK-1R) interaction system is known to play a key role ... Background: Although chemotherapy is predominantly used for cancer treatment, it can be ...

Abstract	Background: Although chemotherapy is predominantly used for cancer treatment, it can be ineffective and can induce serious side effects and lead to chemoresistance. It is essential to discover novel drugs that can enhance the antitumor activity and at the same time, counteract the severe side effects, of chemotherapy. The substance P (SP)/neurokinin-1 receptor (NK-1R) interaction system is known to play a key role in the pathogenesis of cancer. Studies with NK-1R antagonists (such as aprepitant) denote that the NK-1R is a potential target for the treatment of cancer. Aprepitant combined with major chemotherapeutic drugs has shown the potential to increase antitumor activity and decrease side effects. Objective: Since malignant tumor cancer cells overexpress the NK-1R, this combination therapy is a promising approach for the treatment of all kinds of cancer. Since aprepitant shows potential of being a broad-antitumor drug, the repurposing of this NK-1R antagonist as an antitumor agent is warranted. Studies pertaining to combination therapy of aprepitant/radiotherapy will also be outlined in this review. The aim of this review is to provide an update on combinational studies pertaining to chemotherapy/radiotherapy and NK-1R antagonist in cancer. Conclusion: This combination strategy once confirmed, might open the door to a new era in chemotherapy and radiotherapy with greater antitumor activity and fewer side effects. This treatment strategy could possibly translate into higher cure rates, better quality of life and fewer sequelae in cancer patients.
MeSH term(s)	Humans ; Aprepitant/adverse effects ; Aprepitant/therapeutic use ; Neurokinin-1 Receptor Antagonists/adverse effects ; Neurokinin-1 Receptor Antagonists/therapeutic use ; Chemoradiotherapy ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Drug Repositioning ; Neoplasms/metabolism ; Neoplasms/therapy ; Substance P/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Chemical Substances	Aprepitant (1NF15YR6UY) ; Neurokinin-1 Receptor Antagonists ; Antineoplastic Agents ; Substance P (33507-63-0)
Language	English
Publishing date	2022-08-11
Publishing country	United Arab Emirates
Document type	Review ; Journal Article
ZDB-ID	1319315-6
ISSN	1875-533X ; 0929-8673
ISSN (online)	1875-533X
ISSN	0929-8673
DOI	10.2174/0929867329666220811152602
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4432: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.

Muñoz, Miguel / Rosso, Marisa / Coveñas, Rafael

Mini reviews in medicinal chemistry

2019 Volume 20, Issue 5, Page(s) 408–417

Abstract: ... One of these targets is the neurokinin-1 receptor (NK-1R). It is well known that the substance P (SP ... for this reason, it is crucial to search for new therapeutic targets in TNBC to develop new therapeutic strategies ... for the treatment of TNBC patients. ...

Abstract	Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death among females. BC cells not showing HER-2/Neu amplification and not expressing estrogen/ progesterone receptors are named triple-negative BC (TNBC) cells. TNBC represents 10-15% of all BC and is associated with an aggressive clinical course. TNBC patient prognosis, survival and response to current therapies are poor and for this reason, it is crucial to search for new therapeutic targets in TNBC to develop new therapeutic strategies. One of these targets is the neurokinin-1 receptor (NK-1R). It is well known that the substance P (SP)/NK-1R system is involved in cancer progression. TNBC cells overexpress the NK-1R and, after binding to this receptor, SP promotes the proliferation/ migration of TNBC cells. Non-peptide NK-1R antagonists (e.g., aprepitant) are known to exert, via the NK-1R, an antitumor action; TNBC cells die by apoptosis. In this review, we update the data on a promising therapeutic innovation: the use of NK-1R antagonists for the treatment of TNBC patients.
MeSH term(s)	Animals ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Female ; Humans ; Neurokinin-1 Receptor Antagonists/adverse effects ; Neurokinin-1 Receptor Antagonists/pharmacology ; Neurokinin-1 Receptor Antagonists/therapeutic use ; Triple Negative Breast Neoplasms/drug therapy
Chemical Substances	Antineoplastic Agents ; Neurokinin-1 Receptor Antagonists
Language	English
Publishing date	2019-11-12
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2104081-3
ISSN	1875-5607 ; 1389-5575
ISSN (online)	1875-5607
ISSN	1389-5575
DOI	10.2174/1389557519666191112152642
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5891: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach.

Muñoz, Miguel / Coveñas, Rafael

Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association

2016 Volume 22, Issue 4, Page(s) 260–268

Abstract: ... cancer and NK-1 receptor antagonists (eg, aprepitant) could be a new promising approach for the treatment ... antagonists are safe and well tolerated. Thus, the NK-1 receptor could be considered as a new target in GI ... After binding to the neurokinin-1 (NK-1) receptor, the undecapeptide substance P (SP) regulates GI ...

Abstract	Gastrointestinal (GI) cancer is the term for a group of cancers affecting the digestive system. After binding to the neurokinin-1 (NK-1) receptor, the undecapeptide substance P (SP) regulates GI cancer cell proliferation and migration for invasion and metastasis, and controls endothelial cell proliferation for angiogenesis. SP also exerts an antiapoptotic effect. Both SP and the NK-1 receptor are located in GI tumor cells, the NK-1 receptor being overexpressed. By contrast, after binding to the NK-1 receptor, NK-1 receptor antagonists elicit the inhibition (epidermal growth factor receptor inhibition) of the proliferation of GI cancer cells in a concentration-dependent manner, induce the death of GI cancer cells by apoptosis, counteract the Warburg effect, inhibit cancer cell migration (counteracting invasion and metastasis), and inhibit angiogenesis (vascular endothelial growth factor inhibition). NK-1 receptor antagonists are safe and well tolerated. Thus, the NK-1 receptor could be considered as a new target in GI cancer and NK-1 receptor antagonists (eg, aprepitant) could be a new promising approach for the treatment of GI cancer.
MeSH term(s)	Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Gastrointestinal Neoplasms/drug therapy ; Gastrointestinal Neoplasms/metabolism ; Gastrointestinal Neoplasms/pathology ; Humans ; Neoplasm Invasiveness ; Neurokinin-1 Receptor Antagonists/pharmacology ; Neurokinin-1 Receptor Antagonists/therapeutic use
Chemical Substances	Antineoplastic Agents ; Neurokinin-1 Receptor Antagonists
Language	English
Publishing date	2016-07
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	2299174-8
ISSN	1998-4049 ; 1319-3767
ISSN (online)	1998-4049
ISSN	1319-3767
DOI	10.4103/1319-3767.187601
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

In stock of ZB MED Cologne/Königswinter

Zs.A 6710: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.

Muñoz, Miguel / González-Ortega, Ana / Rosso, Marisa / Robles-Frias, María José / Carranza, Andres / Salinas-Martín, Manuel Vicente / Coveñas, Rafael

Peptides

2012 Volume 38, Issue 2, Page(s) 318–325

Abstract: ... a promising new target in the treatment of lung cancer and that NK-1R antagonists could be new candidate ... receptor (NK-1R) system plays an important role in the development of cancer: SP and NK-1R antagonists ... antitumor drugs in the treatment of SCLC and NSCLC. ...

Abstract	The last decades have seen no significant progress in extending the survival of lung cancer patients and there is an urgent need to improve current therapies. The substance P (SP)/neurokinin-1 receptor (NK-1R) system plays an important role in the development of cancer: SP and NK-1R antagonists respectively induce cell proliferation and inhibition in human cancer cell lines. No study of the involvement of this system in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells has been carried out in depth. Here, we demonstrate the involvement of the SP/NK-1R system in human H-69 (SCLC) and COR-L23 (NSCLC) cell lines: (1) they express isoforms of the NK-1R and mRNA for the NK-1R; (2) they overexpress the tachykinin 1 gene; (3) the NK-1R is involved in their viability; (4) SP induces their proliferation; (5) NK-1R antagonists (Aprepitant (Emend), L-733,060, L-732,138) inhibit the growth of both cell lines in a concentration-dependent manner; (6) the specific antitumor action of these antagonists against such cells occurs through the NK-1R; and (7) lung cancer cell death is due to apoptosis. We also demonstrate the presence of NK-1Rs and SP in all the human SCLC and NSCLC samples studied. Our findings indicate that the NK-1R may be a promising new target in the treatment of lung cancer and that NK-1R antagonists could be new candidate antitumor drugs in the treatment of SCLC and NSCLC.
MeSH term(s)	Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Lung Neoplasms/chemistry ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Morpholines/chemistry ; Morpholines/pharmacology ; Neurokinin-1 Receptor Antagonists ; Piperidines/chemistry ; Piperidines/pharmacology ; Receptors, Neurokinin-1/analysis ; Receptors, Neurokinin-1/genetics ; Structure-Activity Relationship ; Substance P/analysis ; Substance P/antagonists & inhibitors ; Tryptophan/analogs & derivatives ; Tryptophan/chemistry ; Tryptophan/pharmacology ; Tumor Cells, Cultured
Chemical Substances	Antineoplastic Agents ; Morpholines ; Neurokinin-1 Receptor Antagonists ; Piperidines ; Receptors, Neurokinin-1 ; 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan (148451-96-1) ; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine (148700-85-0) ; aprepitant (1NF15YR6UY) ; Substance P (33507-63-0) ; Tryptophan (8DUH1N11BX)
Language	English
Publishing date	2012-12
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	769028-9
ISSN	1873-5169 ; 0196-9781
ISSN (online)	1873-5169
ISSN	0196-9781
DOI	10.1016/j.peptides.2012.09.024
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1649: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer

Miguel Muñoz / Rafael Coveñas

Saudi Journal of Gastroenterology, Vol 22, Iss 4, Pp 260-

A new approach

2016 Volume 268

Abstract	Gastrointestinal (GI) cancer is the term for a group of cancers affecting the digestive system. After binding to the neurokinin-1 (NK-1) receptor, the undecapeptide substance P (SP) regulates GI cancer cell proliferation and migration for invasion and metastasis, and controls endothelial cell proliferation for angiogenesis. SP also exerts an antiapoptotic effect. Both SP and the NK-1 receptor are located in GI tumor cells, the NK-1 receptor being overexpressed. By contrast, after binding to the NK-1 receptor, NK-1 receptor antagonists elicit the inhibition (epidermal growth factor receptor inhibition) of the proliferation of GI cancer cells in a concentration-dependent manner, induce the death of GI cancer cells by apoptosis, counteract the Warburg effect, inhibit cancer cell migration (counteracting invasion and metastasis), and inhibit angiogenesis (vascular endothelial growth factor inhibition). NK-1 receptor antagonists are safe and well tolerated. Thus, the NK-1 receptor could be considered as a new target in GI cancer and NK-1 receptor antagonists (eg, aprepitant) could be a new promising approach for the treatment of GI cancer.
Keywords	Colorectal cancer ; gastric cancer ; hepatoblastoma ; esophageal carcinoma ; pancreatic cancer ; Diseases of the digestive system. Gastroenterology ; RC799-869 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R
Subject code	610 ; 616
Language	English
Publishing date	2016-01-01T00:00:00Z
Publisher	Medknow Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.

Rosso, Marisa / Muñoz, Miguel / Berger, Michael

TheScientificWorldJournal

2012 Volume 2012, Page(s) 381434

Abstract: ... of NK-1 receptor antagonists as a novel and promising approach for treating patients with cancer is ... binding to the specific neurokinin-1 (NK-1) receptor, the peptide substance P (SP), which is widely ... into a better overall prognosis for patients with cancer, and the search for new drug targets continues. After ...

Abstract	The recent years have witnessed an exponential increase in cancer research, leading to a considerable investment in the field. However, with few exceptions, this effort has not yet translated into a better overall prognosis for patients with cancer, and the search for new drug targets continues. After binding to the specific neurokinin-1 (NK-1) receptor, the peptide substance P (SP), which is widely distributed in both the central and peripheral nervous systems, triggers a wide variety of functions. Antagonists against the NK-1 receptor are safe clinical drugs that are known to have anti-inflammatory, analgesic, anxiolytic, antidepressant, and antiemetic effects. Recently, it has become apparent that SP can induce tumor cell proliferation, angiogenesis, and migration via the NK-1 receptor, and that the SP/NK-1 receptor complex is an integral part of the microenvironment of inflammation and cancer. Therefore, the use of NK-1 receptor antagonists as a novel and promising approach for treating patients with cancer is currently under intense investigation. In this paper, we evaluate the recent scientific developments regarding this receptor system, its role in the microenvironment of inflammation and cancer, and its potentials and pitfalls for the usage as part of modern anticancer strategies.
MeSH term(s)	Emotions ; Humans ; Immunohistochemistry ; Inflammation/pathology ; Inflammation/physiopathology ; Neoplasms/pathology ; Neoplasms/physiopathology ; Neoplasms/psychology ; Receptors, Neurokinin-1/metabolism ; Receptors, Neurokinin-1/physiology ; Substance P/metabolism ; Tumor Microenvironment
Chemical Substances	Receptors, Neurokinin-1 ; Substance P (33507-63-0)
Language	English
Publishing date	2012-04-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2075968-X
ISSN	1537-744X ; 1537-744X
ISSN (online)	1537-744X
ISSN	1537-744X
DOI	10.1100/2012/381434
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.

Muñoz, Miguel / González-Ortega, Ana / Salinas-Martín, Manuel Vicente / Carranza, Andrés / Garcia-Recio, Susana / Almendro, Vanessa / Coveñas, Rafael

International journal of oncology

2014 Volume 45, Issue 4, Page(s) 1658–1672

Abstract: ... receptor may be a promising target in the treatment of BC and NK-1 receptor antagonists could be candidates ... The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in the development ... as a new antitumor drug in the treatment of BC. ...

Abstract	The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in the development of cancer. No in-depth studies of the involvement of this system in breast cancer (BC) have been carried out, and the action exerted by the drug aprepitant on BC cells is currently unknown. We show the involvement of this system in human BC cell lines: i) these cells express mRNA for the NK-1 receptor; ii) they overexpress NK-1 receptors; iii) the NK-1 receptor is involved in their viability; iv) SP induces their proliferation; v) NK-1 receptor antagonists block SP-induced mitogen stimulation of these cells; vi) the specific antitumor action of such antagonists on these cells occurs through the NK-1 receptor; and vii) BC cell death is due to apoptosis. We also found NK-1 receptors and SP in all human BC samples studied. The NK-1 receptor may be a promising target in the treatment of BC and NK-1 receptor antagonists could be candidates as a new antitumor drug in the treatment of BC.
MeSH term(s)	Antineoplastic Agents/pharmacology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Knockdown Techniques ; Humans ; MCF-7 Cells ; Morpholines/pharmacology ; Neurokinin-1 Receptor Antagonists/pharmacology ; Piperidines/pharmacology ; Receptors, Neurokinin-1/genetics ; Receptors, Neurokinin-1/metabolism ; Substance P/metabolism ; Tryptophan/analogs & derivatives ; Tryptophan/pharmacology
Chemical Substances	Antineoplastic Agents ; Morpholines ; Neurokinin-1 Receptor Antagonists ; Piperidines ; Receptors, Neurokinin-1 ; 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan (148451-96-1) ; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine (148700-85-0) ; aprepitant (1NF15YR6UY) ; Substance P (33507-63-0) ; Tryptophan (8DUH1N11BX)
Language	English
Publishing date	2014-10
Publishing country	Greece
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1154403-x
ISSN	1791-2423 ; 1019-6439
ISSN (online)	1791-2423
ISSN	1019-6439
DOI	10.3892/ijo.2014.2565
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3690: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito